piribedil has been researched along with Acute Myelogenous Leukemia in 1 studies
Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, X | 1 |
| Zheng, X | 1 |
| Yang, H | 1 |
| Yan, J | 1 |
| Fu, X | 1 |
| Wei, R | 1 |
| Xu, X | 1 |
| Zhang, Z | 1 |
| Yu, A | 1 |
| Zhou, K | 1 |
| Ding, J | 1 |
| Geng, M | 1 |
| Huang, X | 1 |
1 other study available for piribedil and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Differentiation; Cell Proliferation; Dop | 2018 |